Latest News

Category: ASX

See all

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

ASX, News,

Telix today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including...

Read more

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

ASX, News,

Telix today announces its financial results for the financial year ended 31 December 2023....

Read more

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

ASX, News,

Telix today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.)...

Read more

Telix Full Year Results 2023 Investor Webcast Notification

ASX, News,

Telix today advises that it will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February...

Read more

Presentation to J.P. Morgan Healthcare Conference and Q4 Revenue Update

ASX, News,

Telix today advises it is presenting at the 42nd Annual J.P. Morgan Healthcare Conference (8-11 January 2024) in San...

Read more

Appointment of Dr David Cade to Group Chief Medical Officer

ASX, News,

Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging...

Read more

Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591

ASX, News,

Telix Group Chief Medical Officer, Dr Colin Hayward, moderated an expert discussion with global key opinion leaders on the evolving treatment landscape for PSMA-targeted radiopharmaceuticals, including Telix’s first-in-class investigational radio-antibody...

Read more

Telix to Host Expert Forum on PSMA-targeting Radiopharmaceuticals including ProstACT Therapy Program of First-in-Class rADC, TLX591

ASX, News,

Telix today advises it will host an investor webcast on Tuesday, 21 November 2023, from 10.15am – 11.15am AEDT (12:15am CET / 6.15pm EST, 20 November). Telix Group Chief Medical Officer,...

Read more

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

ASX, News,

Telix today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based clinical...

Read more

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

ASX, News,

Telix and Paris-based Mauna Kea Technologies, today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance through a strategic €6.0 million (AU$9.6 million) investment to develop new...

Read more